Table 2.

Signal scores for JAK inhibitors-associated DVT

JAK inhibitor	Total (n)	Cases (n)	ROR (95% CI)	IC (95% CI)
JAK inhibitors	6631	60	2.52* (1.95–3.25)	1.27* (0.41–2.13)
Tofacitinib	2431	24	2.73* (1.82–4.09)	1.34 (− 0.004 to 2.68)
Ruxolitinib	1513	2	0.36 (0.09–1.44)	− 1.12 (− 4.97 to 2.72)
Baricitinib	1338	21	4.37* (2.83–6.73)	1.90* (0.47–3.33)
Peficitinib	651	5	2.11 (0.87–5.09)	0.83 (− 1.90 to 3.55)
Upadacitinib	580	7	3.33* (1.58–7.03)	1.36 (− 1.01 to 3.72)
Filgotinib	233	2	2.36 (0.59–9.50)	0.69 (− 3.17 to 4.55)
Abrocitinib	30	0	–	–

JAK Janus kinase, DVT deep vein thrombosis, ROR reported odds ratio, IC information component

*The adverse events are detected as signals